Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Excitation Dynamics in Hetero-bichromophoric Calixarene Systems.
Tosi I, Segado Centellas M, Campioli E, Iagatti A, Lapini A, Sissa C, Baldini L, Cappelli C, Di Donato M, Sansone F, Santoro F, Terenziani F. Tosi I, et al. Chemphyschem. 2016 Jun 3;17(11):1686-706. doi: 10.1002/cphc.201501065. Epub 2016 Mar 15. Chemphyschem. 2016. PMID: 26867716
A calixarene-based fluorescent ratiometric temperature probe.
Bardi B, Tosi I, Faroldi F, Baldini L, Sansone F, Sissa C, Terenziani F. Bardi B, et al. Among authors: tosi i. Chem Commun (Camb). 2019 Jul 18;55(56):8098-8101. doi: 10.1039/c9cc04577e. Epub 2019 Jun 24. Chem Commun (Camb). 2019. PMID: 31232416
Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
Quirke-McFarlane S, Weinman J, Cook ES, Yiu ZZN, Dand N, Langan SM, Bechman K, Tsakok T, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Barbosa IA, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Galloway JB, Griffiths CEM, Barker JN, Norton S, Smith CH, Mahil SK; PsoProtect study group. Quirke-McFarlane S, et al. Br J Dermatol. 2023 Apr 20;188(5):610-617. doi: 10.1093/bjd/ljac144. Br J Dermatol. 2023. PMID: 36763806
Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial.
Fish M, Rynne J, Jennings A, Lam C, Lamikanra AA, Ratcliff J, Cellone-Trevelin S, Timms E, Jiriha J, Tosi I, Pramanik R, Simmonds P, Seth S, Williams J, Gordon AC, Knight J, Smith DJ, Whalley J, Harrison D, Rowan K, Harvala H, Klenerman P, Estcourt L, Menon DK, Roberts D, Shankar-Hari M; REMAP-CAP Immunoglobulin Domain UK Investigators. Fish M, et al. Among authors: tosi i. Intensive Care Med. 2022 Nov;48(11):1525-1538. doi: 10.1007/s00134-022-06869-w. Epub 2022 Sep 14. Intensive Care Med. 2022. PMID: 36102943 Free PMC article. Clinical Trial.
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Andres-Ejarque R, et al. Among authors: tosi i. Nat Commun. 2021 Dec 16;12(1):7358. doi: 10.1038/s41467-021-27447-6. Nat Commun. 2021. PMID: 34916493 Free PMC article. No abstract available.
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Bégin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chassé M, Cheng AC, Cove ME, Daly J, Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, MacLennan S, Marshall J, McAuley DF, McDyer JF, McGlothlin A, McGuinness S, Miflin G, Montgomery S, Mouncey PR, Murthy S, Nichol A, Parke R, Parker JC, Priddee N, Purcell DFJ, Reyes LF, Richardson P, Robitaille N, Rowan KM, Rynne J, Saito H, Santos M, Saunders CT, Serpa Neto A, Seymour CW, Silversides JA, Tinmouth AA, Triulzi DJ, Turner AM, van de Veerdonk F, Walsh TS, Wood EM, Berry S, Lewis RJ, Menon DK, McArthur C, Zarychanski R, Angus DC, Webb SA, Roberts DJ, Shankar-Hari M. Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178. JAMA. 2021. PMID: 34606578 Free PMC article. Clinical Trial.
49 results